Fingolimod (FTY720): First approved oral therapy for multiple sclerosis

Journal of Pharmacology and Pharmacotherapeutics

Volumn 2, Issue 1, 2011, Pages 49-51

  Sharma, Sushil ^a   Mathur, A G ^a   Pradhan, Sapna ^a   Singh, D B ^a   Gupta, Sparsh ^a  

^a Army College of Medical Sciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; KETOCONAZOLE; PLACEBO;

ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL EFFECTIVENESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEART RATE; HUMAN; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; RETINA MACULA EDEMA; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; TREATMENT DURATION;

EID: 80052757847     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.77118     Document Type: Article

References (20)

1. Noseworthy JH, Lucchinetti C F, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
2. Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31.
3. Rosati G. The prevalence of multiple sclerosis in the world: An update. Neurol Sci 2001;22:117-39.
4. Vasiliou S. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drugs Today 2010;46:315-25.
5. FDA approves first oral drug to reduce MS relapses. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm. [cited in 2010].
6. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747.
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 1998;338: 278-85.
8. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor. Nature 2004;427:355-60.
9. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-9.
10. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277:21453-7.
11. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4:1019-25.
12. Jackson SJ, Baker D, Giovannoni G. Fingolimod enhances myelin basic protein expression and modulates cytokine production following an interferon-gamma mediated insult in the whole brain aggregate cell culture system. Neurology 2009;72:377-8.
13. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel J P. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71.
14. Coelho R P, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007;323:626-35.
15. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther Drug Monit 2004;26:585-7.
16. Kovarik JM, Dole K, Riviere GJ, Pommier F, Maton S, Jin Y, et al. Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition. J Clin Pharmacol 2009;49:212-8
17. Kappos L, Radue E W, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
18. Cohen JA, Barkhof F, Comi G, Hartung H P, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
19. Kappos L, Antel J, Comi G, Montalban X, Connor O P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40.
20. Carroll WM. Oral therapy for multiple sclerosis: Sea change or incremental step? N Engl J Med 2010;362:456-8.